Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01880723 · ClinicalTrials.gov registry record · NA
Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis
A NA study, sponsored by University of Arizona.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT01880723 is a NA study that has completed, run by University of Arizona. The registered enrollment target is 32 participants.
The verdict
NCT01880723, a NA study, has completed, sponsored by University of Arizona.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Our aims were to determine if exhaled breath condensate (EBC) could detect differences in ion regulation between cystic fibrosis (CF) and healthy and measure the effect of the albuterol on EBC ions in these populations. We hypothesized EBC chloride and sodium would be lower in CF patients at baseline and that albuterol would decrease EBC sodium and increase EBC chloride.
Interventions
- DRUG Albuterol
- DRUG Placebo saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01880723
The ClinicalTrials.gov registry entry for NCT01880723 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albuterol is the first listed.
NCT01880723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01880723 about?
NCT01880723 is a clinical study titled "Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis". Our aims were to determine if exhaled breath condensate (EBC) could detect differences in ion regulation between cystic fibrosis (CF) and healthy and measure the effect of the albuterol on EBC ions in these populations. We hypothesized EBC chloride and sodium would be lower in CF patients at baselin...
What is the current status of trial NCT01880723?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2009-05. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01880723?
The interventions under investigation include: Albuterol (DRUG), Placebo saline (DRUG).
Who is sponsoring clinical trial NCT01880723?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.